The price of Arcus Biosciences Inc (NYSE: RCUS) closed at $14.49 in the last session, up 3.13% from day before closing price of $14.05. In other words, the price has increased by $+0.44 from its previous closing price. On the day, 540582 shares were traded. RCUS stock price reached its highest trading level at $14.81 during the session, while it also had its lowest trading level at $14.19.
Elon Musk just Triggered a BOOM in These Stocks
Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"
Click Here to Download the FREE Report.
Sponsored
Ratios:
We take a closer look at RCUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.41 and its Current Ratio is at 4.41. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 22 when Jarrett Jennifer sold 21,369 shares for $19.99 per share. The transaction valued at 427,166 led to the insider holds 302,691 shares of the business.
Jarrett Jennifer sold 45,000 shares of RCUS for $911,250 on Jul 28. The Chief Operating Officer now owns 336,566 shares after completing the transaction at $20.25 per share. On Jul 03, another insider, Azoy Alexander, who serves as the Chief Accounting Officer of the company, sold 1,018 shares for $20.41 each. As a result, the insider received 20,777 and left with 11,596 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1.08B and an Enterprise Value of 294.66M. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.07 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 2.46 whereas that against EBITDA is -1.06.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $36.13, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is 16.89, while the 200-Day Moving Average is calculated to be 18.63.
Shares Statistics:
According to the various share statistics, RCUS traded on average about 850.41K shares per day over the past 3-months and 941.23k shares per day over the past 10 days. A total of 72.90M shares are outstanding, with a floating share count of 48.18M. Insiders hold about 35.63% of the company’s shares, while institutions hold 65.98% stake in the company. Shares short for RCUS as of Oct 30, 2023 were 6.92M with a Short Ratio of 6.92M, compared to 6.62M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.25% and a Short% of Float of 15.54%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.02 for the current quarter, with a high estimate of -$0.82 and a low estimate of -$1.21, while EPS last year was -$0.93. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.62 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$3.54 and -$4.31 for the fiscal current year, implying an average EPS of -$4.01. EPS for the following year is -$4.03, with 9 analysts recommending between -$1.64 and -$5.37.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $28.33M. It ranges from a high estimate of $34.3M to a low estimate of $22.5M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $34M, an estimated decrease of -16.70% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $39M, an increase of 56.00% over than the figure of -$16.70% in the same quarter last year. There is a high estimate of $72.5M for the next quarter, whereas the lowest estimate is $25M.
A total of 9 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $120.3M, while the lowest revenue estimate was $99M, resulting in an average revenue estimate of $112.91M. In the same quarter a year ago, actual revenue was $112M, up 0.80% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $146.22M in the next fiscal year. The high estimate is $347.16M and the low estimate is $90M. The average revenue growth estimate for next year is up 29.50% from the average revenue estimate for this year.
